Tandem Diabetes Care posts Q3 2026 revenue of $283.7 M, improves margin and reaffirms 2026 guidance
+1 new source since this summary was written
Tandem Diabetes Care reported third‑quarter 2026 revenue of $283.69 million, a reported 13.8% year‑over‑year increase, and narrowed its net loss to $7.09 million, or $0.10 per diluted share. Gross margin rose to 57% from 54% and adjusted EBITDA margin reached 6% of sales. The company reaffirmed its full‑year 2026 outlook of $730 million‑$745 million U.S. sales and $335 million‑$340 million international sales and expects FDA clearance for its Mobi Tubeless system in the fourth quarter.
Why it matters
The company’s guidance reaffirmation and stronger margin suggest continued cash generation, with $443 million in cash and investments at quarter‑end. Analysts note the beat and margin lift as reasons to raise price targets.
Key facts
- 1Revenue was $283.69 million for the quarter, reported as “Sales”. tradingview.com
- 2Revenue grew 13.8% year‑over‑year on a reported basis. tradingview.com
- 3Net loss was $7.09 million, reported. tradingview.com
- 4Diluted EPS (net loss per share) was $‑0.10, reported. tradingview.com
- 5Gross margin improved to 57% from 54% on a reported basis. tradingview.com
- 6Adjusted EBITDA margin was 6% of sales, reported. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.